New hope for lung cancer patients who stop responding to standard therapy
NCT ID NCT05184712
First seen Mar 21, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) live longer without their cancer growing. Participants have already tried and failed an EGFR-targeted pill. About 322 adults will receive either AK112 or a placebo, plus chemo, to see if the combination improves outcomes like progression-free survival and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.